GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Turk Ilac ve Serum Sanayi (IST:TRILC) » Definitions » Debt-to-Revenue

Turk Ilac ve Serumnayi (IST:TRILC) Debt-to-Revenue : 0.19 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Turk Ilac ve Serumnayi Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Turk Ilac ve Serumnayi's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₺306 Mil. Turk Ilac ve Serumnayi's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₺26 Mil. Turk Ilac ve Serumnayi's annualized Revenue for the quarter that ended in Sep. 2023 was ₺1,744 Mil. Turk Ilac ve Serumnayi's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 was 0.19.


Turk Ilac ve Serumnayi Debt-to-Revenue Historical Data

The historical data trend for Turk Ilac ve Serumnayi's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turk Ilac ve Serumnayi Debt-to-Revenue Chart

Turk Ilac ve Serumnayi Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Revenue
Get a 7-Day Free Trial 0.69 0.74 0.65 0.29 0.37

Turk Ilac ve Serumnayi Quarterly Data
Dec17 Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.46 0.22 0.28 0.19

Competitive Comparison of Turk Ilac ve Serumnayi's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Turk Ilac ve Serumnayi's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Turk Ilac ve Serumnayi's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Turk Ilac ve Serumnayi's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Turk Ilac ve Serumnayi's Debt-to-Revenue falls into.



Turk Ilac ve Serumnayi Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Turk Ilac ve Serumnayi's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(291.644 + 18.882) / 833.438
=0.37

Turk Ilac ve Serumnayi's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(306.184 + 25.506) / 1743.528
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2023) Revenue data.


Turk Ilac ve Serumnayi Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Turk Ilac ve Serumnayi's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Turk Ilac ve Serumnayi (IST:TRILC) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Bügduz Mah. Enver Pasa Cad., No: 8 Akyurt, Ankara, TUR, TR 06750
Turk Ilac ve Serum Sanayi is engaged in the production of human pharmaceuticals and vaccines.

Turk Ilac ve Serumnayi (IST:TRILC) Headlines

No Headlines